Abstract:

BACKGROUND: There is multiple reasons for malignant tumor after the renal transplant, its high morbidity rate is closely related to the long term utilize of large dose of immunosuppressant.
OBJECTIVE: To discusses the relativity between tumors and the immunosuppressant by retrospective analysis the utilize of immunosuppressant after renal transplantation, the morbidity rate of malignant tumor, the time of tumor occurrences and its characteristics, as well as other related factors.
METHODS: Sixteen patients with malignant tumors were selected from 512 renal transplant patients to perform the retrospective analysis. Fifteen patients were treated with mycophenolate mofetil+cyclosporine A+methylprednisolone, and one patient treated with mycophenolate mofetil+azathioprine+methylprednisolone. After renal transplantation, 12 patients were treated with surgery, one patient was treated with chemotherapy alone, and three patients had metastases in the advanced stage or gave up the treatment.
RESULTS AND CONCLUSION: The tumor incidence rate of the patients after renal transplantation was 3.13%, among them, six cases with urinary tumors (37.5%), four cases of gastrointestinal tumors (25.0%, two cases of colon cancer, one case of rectal cancer and one case of gastric cancer), three cases of liver cancer (18.75%), one case of lung cancer (6.25%), one case of ovarian cancer (6.25%) and one case of skin cancer (6.25%). Among the renal transplant patients, the most commonly malignant tumor is urinary tumor and followed by gastrointestinal tumor. For the renal transplant patients, reducing the dose of immunosuppressant is one of the primary key factors that can help to prevent the occurrences of tumor after the renal transplant and increase the long term survival rate of renal transplant patients.